Pancreatic Cancer Research

Journal articleEur Rev Med Pharmacol Sci2018

Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer.

Journal
Eur Rev Med Pharmacol Sci
Published
1 August 2018
Citations
17
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Objective Increasing evidence indicates that dysregulation of miRNAs is involved in tumor progression and development. We aimed to determine potential values of miR-629 as a serum diagnostic and prognostic biomarker in pancreatic cancer (PC). … Excerpt only: this text is the publisher’s. Read it in full at the source.